Mesalamine
Treatment for Inflammatory Bowel Disease
Typical Dosage: 1.2-4.8 g/day orally or 1g rectally daily
Effectiveness
45%
Safety Score
78%
Clinical Trials
160
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
78
DangerousModerateSafe
Treatment Details
Dosage Range
1.2-4.8 g/day orally or 1g rectally daily
Time to Effect
4-8 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,000
Monitoring:$500
Side Effect Mgmt:$100
Total Annual:$2,600
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$30,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$4,333
Cost per Remission
$6,500
Prescription Access Economics
Annual Societal Loss per Patient
$-10,085
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$375/year
Time Cost
$300/year
Travel + wait time
Insurance Admin Cost
$240/year
Prior auth, claims
Rx Price
$2,000/year
Potential OTC Price
$1,000/year
Estimated if OTC available
Early Treatment Benefit
+0.10 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWMesalamine Outcomes
for Inflammatory Bowel Disease
Efficacy Outcomes
Overall Effectiveness
+45%
Response Rate
+60%
Remission Rate
+40%
Common Side Effects
Headache
+8%
Nausea/Diarrhea/Abdominal pain
+7%
Myocarditis/Pericarditis
+0.5%
Nephrotoxicity
+0.5%
Sources:
Active Clinical Trials
5 active trials recruiting for Mesalamine in Inflammatory Bowel Disease
Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease
NCT05986136RECRUITINGPHASE2, PHASE3
50 participants
INTERVENTIONAL
Al Mansurah, Egypt
Started: Aug 20, 2023
Fenofibrate in Ulcerative Colitis
NCT05753267RECRUITINGPHASE2, PHASE3
60 participants
INTERVENTIONAL
Tanta, Egypt
Started: Feb 28, 2023
Metformin as Added on Therapy in Patients With Ulcerative Colitis
NCT05574387RECRUITINGPHASE2
46 participants
INTERVENTIONAL
Al Mansurah, Egypt
Started: Jan 20, 2023
Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.
NCT05575505RECRUITINGPHASE2
44 participants
INTERVENTIONAL
Al Mansurah, Egypt
Started: Feb 2, 2023
Efficacy and Safety of Discontinuing 5-ASA in Patients With Inflammatory Bowel Disease
NCT06878495NOT YET RECRUITINGNA
100 participants
INTERVENTIONAL
Started: Jun 15, 2025
Completed Clinical Trials
12 completed trials for Mesalamine in Inflammatory Bowel Disease
Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis
NCT05988528COMPLETEDPHASE2, PHASE3
50 participants
INTERVENTIONAL
Tanta, Egypt
Started: Aug 20, 2023
Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis
NCT05781698COMPLETEDPHASE2
60 participants
INTERVENTIONAL
Tanta, Egypt
Started: Mar 20, 2023
Atorvastatin Efficacy and Safety in Patients With Ulcerative Colitis
NCT05567068COMPLETEDPHASE2
54 participants
INTERVENTIONAL
Al Mansurah, Egypt
Started: Feb 1, 2023
Metformin in Patients With Ulcerative Colitis Treated With Mesalamine
NCT05553704COMPLETEDPHASE2
60 participants
INTERVENTIONAL
Al Mansurah, Egypt
Started: Nov 1, 2022
Minocyclin in Ulcerative Colitis as Added on Therapy
NCT06201793COMPLETEDPHASE2
46 participants
INTERVENTIONAL
Al Mansurah, Egypt
Started: Jan 22, 2024
The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels
NCT00167882COMPLETEDPHASE4
24 participants
INTERVENTIONAL
Sittard, Netherlands
Started: Jul 1, 2005
Pentoxifylline as Adjunctive Therapy in Patients With Ulcerative Colitis
NCT05558761COMPLETEDPHASE2
50 participants
INTERVENTIONAL
Al Mansurah, Egypt
Started: Oct 10, 2022
Atorvastatin in Patients With Ulcerative Colitis
NCT05561062COMPLETEDPHASE2
50 participants
INTERVENTIONAL
Al Mansurah, Egypt
Started: Dec 1, 2022
Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)
NCT01534312COMPLETEDNA
24 participants
INTERVENTIONAL
Aarhus C, Denmark
Started: Jan 1, 2012
Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)
NCT01327300COMPLETEDPHASE2
7 participants
INTERVENTIONAL
Gainesville, United States
Started: Mar 1, 2010
Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease
NCT03445624COMPLETED
60 participants
OBSERVATIONAL
Asyut, Egypt
Started: Jul 1, 2018
Effectiveness of Fecal Microbiota Transplantation as add-on Therapy in Mild-to-moderate Ulcerative Colitis
NCT05538026COMPLETEDNA
53 participants
INTERVENTIONAL
Kyiv, Ukraine +1 more
Started: Sep 1, 2020
Showing 20 of 163 total trials